Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression

Journal of Immunology

Volumn 180, Issue 9, 2008, Pages 6421-6429

  Pachot, Alexandre ^a   Cazalis, Marie Angélique ^a   Venet, Fabienne ^b   Turrel, Fanny ^a   Faudot, Caroline ^a   Voirin, Nicolas ^a   Diasparra, Jennifer ^a   Bourgoin, Naïck ^a   Poitevin, Françoise ^b   Mougin, Bruno ^a   Lepape, Alain ^c   Monneret, Guillaume ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMOKINE RECEPTOR CX3CR1; CORTICOSTEROID; FRACTALKINE; MESSENGER RNA; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL FUNCTION; CELL MEMBRANE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; BLOOD; CELL MOTION; DOWN REGULATION; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADRENAL CORTEX HORMONES; ADULT; AGED; CELL MOVEMENT; CHEMOKINE CX3CL1; DOWN-REGULATION; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNE TOLERANCE; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CHEMOKINE; RNA, MESSENGER; SHOCK, SEPTIC; STAPHYLOCOCCUS AUREUS;

EID: 44449152668     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.9.6421     Document Type: Article

References (61)

1. Annane, D., E. Bellissant, and J. M. Cavaillon. 2005. Septic shock. Lancet 365: 63-78. (Pubitemid 40082148)
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310. (Pubitemid 32641789)
3. Hunter, P. 2006. Sepsis under siege: a new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO Rep. 7: 667-669. (Pubitemid 43986259)
4. Munford, R. S., and J. Pugin. 2001. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 163: 316-321. (Pubitemid 32158505)
5. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150. (Pubitemid 36056721)
6. Monneret, G., A. Lepape, N. Voirin, J. Bohé, F. Venet, A. L. Debard, H. Thizy, J. Bienvenu, F. Gueyffier, and P. Vanhems. 2006. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32: 1175-1183. (Pubitemid 44232412)
7. O'Sullivan, S. T., J. A. Lederer, A. F. Horgan, D. H. Chin, J. A. Mannick, and M. L. Rodrick. 1995. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann. Surg. 222: 482-490.
8. Asadullah, K., C. Woiciechowsky, W. D. Docke, K. Egerer, W. J. Kox, S. Vogel, W. Sterry, and H. D. Volk. 1995. Very low monocytic HLA-DR expression indicates high risk of infection: immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur. J. Emerg. Med. 2: 184-190.
9. Muehlstedt, S. G., M. Lyte, and J. L. Rodriguez. 2002. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock 17: 443-450.
10. Le Tulzo, Y., C. Pangault, L. Amiot, V. Guilloux, O. Tribut, C. Arvieux, C. Camus, R. Fauchet, R. Thomas, and B. Drenou. 2004. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am. J. Respir. Crit. Care Med. 169: 1144-1151. (Pubitemid 38624795)
11. Lekkou, A., M. Karakantza, A. Mouzaki, F. Kalfarentzos, and C. A. Gogos. 2004. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin. Diagn. Lab. Immunol. 11: 161-167. (Pubitemid 38090671)
12. Pachot, A., A. Lepape, S. Vey, J. Bienvenu, B. Mougin, and G. Monneret. 2006. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol. Lett. 106: 63-71. (Pubitemid 44109733)
13. Imai, T., K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. Takagi, H. Nomiyama, T. J. Schall, and O. Yoshie. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530. (Pubitemid 27508241)
14. Hundhausen, C., D. Misztela, T. A. Berkhout, N. Broadway, P. Saftig, K. Reiss, D. Hartmann, F. Fahrenholz, R. Postina, V. Matthews, et al. 2003. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186-1195. (Pubitemid 36988021)
15. Garton, K. J., P. J. Gough, C. P. Blobel, G. Murphy, D. R. Greaves, P. J. Dempsey, and E. W. Raines. 2001. Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276: 37993-38001. (Pubitemid 37384050)
16. Umehara, H., E. T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai. 2004. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24: 34-40. (Pubitemid 38082409)
17. Fraticelli, P., M. Sironi, G. Bianchi, D. D'Ambrosio, C. Albanesi, A. Stoppacciaro, M. Chieppa, P. Allavena, L. Ruco, G. Girolomoni, et al. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 107: 1173-1181. (Pubitemid 32422914)
18. Imaizumi, T., H. Yoshida, and K. Satoh. 2004. Regulation of CX3CL1/fractalkine expression in endothelial cells. J. Atheroscler. Thromb. 11: 15-21.
19. Fujimoto, K., T. Imaizumi, H. Yoshida, S. Takanashi, K. Okumura, and K. Satoh. 2001. Interferon-γ stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am. J. Respir. Cell Mol. Biol. 25: 233-238. (Pubitemid 32752450)
20. Fong, A. M., L. A. Robinson, D. A. Steeber, T. F. Tedder, O. Yoshie, T. Imai, and D. D. Patel. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188: 1413-1419. (Pubitemid 28489578)
21. Haskell, C. A., M. D. Cleary, and I. F. Charo. 2000. Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation correlate with cell adhesion. J. Biol. Chem. 275: 34183-34189.
22. Ancuta, P., R. Rao, A. Moses, A. Mehle, S. K. Shaw, F. W. Luscinskas, and D. Gabuzda. 2003. Fractalkine preferentially mediates arrest and migration of CD16 monocytes. J. Exp. Med. 197: 1701-1707. (Pubitemid 36745345)
23. Nanki, T., T. Imai, K. Nagasaka, Y. Urasaki, Y. Nonomura, K. Taniguchi, K. Hayashida, J. Hasegawa, O. Yoshie, and N. Miyasaka. 2002. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 46: 2878-2883. (Pubitemid 35315878)
24. Nishimura, M., H. Umehara, T. Nakayama, O. Yoneda, K. Hieshima, M. Kakizaki, N. Dohmae, O. Yoshie, and T. Imai. 2002. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin/granzyme B cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168: 6173-6180. (Pubitemid 34620036)
25. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. Schein, and W. J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
26. Le Gall, J. R., S. Lemeshow, and F. Saulnier. 1993. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. J. Am. Med. Assoc. 270: 2957-2963. (Pubitemid 24000804)
27. Pachot, A., G. Monneret, A. Brion, F. Venet, J. Bohé, J. Bienvenu, B. Mougin, and A. Lepape. 2005. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit. Care Med. 33: 31-38. (Pubitemid 40116533)
28. Pachot, A., J. L. Blond, B. Mougin, and P. Miossec. 2004. Peptidylpropyl isomerase B (PPIB): a suitable reference gene for mRNA quantification in peripheral whole blood. J. Biotechnol. 114: 121-124. (Pubitemid 39298290)
29. + regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177: 6540-6547.
30. Irizarry, R. A., B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs, and T. P. Speed. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31: e15.
31. Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, and T. P. Speed. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
32. Monneret, G., H. Li, J. Vasilescu, J. Rokach, and W. S. Powell. 2002. 15-Deoxy-δ 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J. Immunol. 168: 3563-3569.
33. Monneret, G., N. Elmenkouri, J. Bohe, A. L. Debard, M. C. Gutowski, J. Bienvenu, and A. Lepape. 2002. Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin. Chem. 48: 1589-1592.
34. ++ monocytes are a major source of TNF. J. Immunol. 168: 3536-3542.
35. + blood monocytes is expanded in sepsis patients. Blood 82: 3170-3176.
36. Jiang, Y., D. I. Beller, G. Frendl, and D. T. Graves. 1992. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J. Immunol. 148: 2423-2428.
37. Stievano, L., E. Piovan, and A. Amadori. 2004. C and CX3C chemokines: cell sources and physiopathological implications. Crit. Rev. Immunol. 24: 205-228. (Pubitemid 39419499)
38. Wolk, K., W. D. Docke, V. von Baehr, H. D. Volk, and R. Sabat. 2000. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96: 218-223. (Pubitemid 30456474)
39. Adib-Conquy, M., C. Adrie, P. Moine, K. Asehnoune, C. Fitting, M. R. Pinsky, J. F. Dhainaut, and J. M. Cavaillon. 2000. NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am. J. Respir. Crit. Care Med. 162: 1877-1883.
40. Monneret, G., M. E. Finck, F. Venet, A. L. Debard, J. Bohe, J. Bienvenu, and A. Lepape. 2004. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol. Lett. 95: 193-198. (Pubitemid 39237665)
41. + T lymphocytes in humans. J. Immunol. 166: 6952-6963.
42. Hotchkiss, R. S., and D. W. Nicholson. 2006. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6: 813-822. (Pubitemid 44631650)
43. Manjuck, J., D. C. Saha, M. Astiz, L. J. Eales, and E. C. Rackow. 2000. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. J. Lab. Clin. Med. 135: 153-160. (Pubitemid 30105074)
44. Heidecke, C. D., T. Hensler, H. Weighardt, N. Zantl, H. Wagner, J. R. Siewert, and B. Holzmann. 1999. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am. J. Surg. 178: 288-292.
45. + regulatory T cells in sepsis-induced immunoparalysis. Crit. Care Med. 31: 2068-2071.
46. Cavaillon, J. M., and M. Adib-Conquy. 2005. Monocytes/macrophages and sepsis. Crit. Care Med. 33: S506-S509. (Pubitemid 41786002)
47. Munoz, C., J. Carlet, C. Fitting, B. Misset, J. P. Bleriot, and J. M. Cavaillon. 1991. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88: 1747-1754.
48. Feezor, R. J., H. V. Baker, W. Xiao, W. A. Lee, T. S. Huber, M. Mindrinos, R. A. Kim, L. Ruiz-Taylor, L. L. Moldawer, R. W. Davis, and J. M. Seeger. 2004. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J. Immunol. 172: 7103-7109. (Pubitemid 38669153)
49. Heidecke, C. D., H. Weighardt, T. Hensler, H. Bartels, and B. Holzmann. 2000. Immune paralysis of T-lymphocytes and monocytes in postoperative abdominal sepsis: correlation of immune function with survival. Chirurg 71: 159-165.
50. Weighardt, H., C. D. Heidecke, K. Emmanuilidis, S. Maier, H. Bartels, J. R. Siewert, and B. Holzmann. 2000. Sepsis after major visceral surgery is associated with sustained and interferon-γ-resistant defects of monocyte cytokine production. Surgery 127: 309-315. (Pubitemid 30140629)
51. Cummings, C. J., T. R. Martin, C. W. Frevert, J. M. Quan, V. A. Wong, S. M. Mongovin, T. R. Hagen, K. P. Steinberg, and R. B. Goodman. 1999. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J. Immunol. 162: 2341-2346. (Pubitemid 29288860)
52. Heesen, M., R. Renckens, A. F. de Vos, D. Kunz, and P. T. van der. 2006. Human endotoxemia induces down-regulation of monocyte CC chemokine receptor 2. Clin. Vaccine Immunol. 13: 156-159.
53. Auffray, C., D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. Cumano, G. Lauvau, and F. Geissmann. 2007. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666-670. (Pubitemid 47229966)
54. Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik, and T. J. Schall. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644.
55. Hack, C. E., and S. Zeerleder. 2001. The endothelium in sepsis: source of and a target for inflammation. Crit. Care Med. 29: S21-S27. (Pubitemid 32681578)
56. Pugin, J. 2007. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found. Symp. 280: 21-27.
57. Chandrasekar, B., S. Mummidi, R. P. Perla, S. Bysani, N. O. Dulin, F. Liu, and P. C. Melby. 2003. Fractalkine (CX3CL1) stimulated by nuclear factor κB (NF-κB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem. J. 373: 547-558. (Pubitemid 36897857)
58. Kremlev, S. G., and C. Palmer. 2005. Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J. Neuroimmunol. 162: 71-80. (Pubitemid 40503100)
59. Hotchkiss, R. S., P. E. Swanson, B. D. Freeman, K. W. Tinsley, J. P. Cobb, G. M. Matuschak, T. G. Buchman, and I. E. Karl. 1999. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27: 1230-1251. (Pubitemid 29379358)
60. Wesche-Soldato, D. E., R. Z. Swan, C. S. Chung, and A. Ayala. 2007. The apoptotic pathway as a therapeutic target in sepsis. Curr. Drug Targets 8: 493-500. (Pubitemid 46672616)
61. Wolk, K., C. Hoflich, H. Zuckermann-Becker, W. D. Docke, H. D. Volk, and R. Sabat. 2007. Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit. Care Med. 35: 458-467. (Pubitemid 46148536)